KFAS
JBIO

Keating Financial Advisory Services’s Jade Biosciences JBIO Stock Holding History

Keating Financial Advisory Services’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22 Hold
1
– – ﹤0.01% 2575
2026
Q1 		$14 Buy
+1
New +$14 ﹤0.01% 2534

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Keating Financial Advisory Services's JBIO Position: Q2 2026 in Review

Keating Financial Advisory Services held its Jade Biosciences (JBIO) position steady in Q2 2026 at 1 share worth $22. The position accounts for ﹤0.01% of the portfolio, ranked #2575.

Keating Financial Advisory Services first reported a position in JBIO in Q1 2026 and has held it in 2 quarters since. 154 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • Keating Financial Advisory Services held 1 share of Jade Biosciences worth $22 as of Q2 2026.
  • Keating Financial Advisory Services left its Jade Biosciences share count unchanged in Q2 2026.
  • Jade Biosciences made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #2575 holding.
  • Keating Financial Advisory Services first reported a position in Jade Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 154 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.